MimiVax, Inc. Company Profile, Contacts & Intelligence

MimiVax, Inc. Overview

Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma. Additional indications are being evaluated through: - Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) - Phase 1 in Neuro-Endocrine Tumors (NET) - Pilot Study in Pediatric High Grade Glioma, recurrent/relapsed Medulloblastoma and DIPG

Headquarters

Buffalo, Ny, United States

Website

www.mimivax.com

Industry

Biotechnology Research

Founded

2012

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

MimiVax, Inc. Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

MimiVax, Inc. People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

MimiVax, Inc. Workforce Composition

Seniority breakdown across 3 visible profiles.

Compare Similar Companies to MimiVax, Inc.

Explore companies in related markets and compare their industry and employee estimates.